
Q2 2025: 7 FDA Decisions to Watch in the Realm of Oncology
Following a busy first quarter marked by multiple high-impact approvals, the momentum heading into Q2 2025 is strong. Some Q1 highlights? Acalabrutinib (Calquence) plus bendamustine and rituximab (Rituxan) redefined standard first-line treatment for older …